Fatigue ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 60 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05378100 (ClinicalTrials.gov) | January 1, 2023 | 12/5/2022 | Ketamine for Multiple Sclerosis Fatigue | Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS) | Multiple Sclerosis Fatigue | Drug: Ketamine;Drug: Midazolam | Johns Hopkins University | United States Department of Defense | Recruiting | 18 Years | 65 Years | All | 110 | Phase 2 | United States |
| 2 | NCT04880577 (ClinicalTrials.gov) | September 15, 2022 | 30/4/2021 | Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis | Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting;Fatigue | Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];Drug: Placebo | Massachusetts General Hospital | Gilead Sciences | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | United States |
| 3 | EUCTR2021-004868-95-ES (EUCTR) | 26/05/2022 | 22/12/2021 | AMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUE IN MULTIPLE SCLEROSIS | AMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUE IN MULTIPLE SCLEROSIS: PHASE III STUDY, CONTROLLED, RANDOMIZED, CROSSED OVER AND DOUBLE BLIND - FETEM | Fatigue in multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Amantadine Level Product Name: Amantadine INN or Proposed INN: INN Other descriptive name: AMANTADINE HYDROCHLORIDE | Fundación para la Inv. Biomédica Hospital Clínico San Carlos | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 144 | Phase 4 | Spain | ||
| 4 | NCT05319093 (ClinicalTrials.gov) | April 2022 | 1/4/2022 | Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients | Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients | Fatigue;Multiple Sclerosis | Drug: Ozanimod | Brigham and Women's Hospital | Bristol-Myers Squibb | Not yet recruiting | 18 Years | N/A | All | 40 | NULL | |
| 5 | NCT04764383 (ClinicalTrials.gov) | January 1, 2022 | 18/2/2021 | Histaminergic Basis of Fatigue in Multiple Sclerosis | Histaminergic Basis of Fatigue in Multiple Sclerosis | Multiple Sclerosis | Drug: L-Histidine;Drug: Placebo;Drug: Lodosyn | University of Miami | NULL | Withdrawn | 18 Years | 60 Years | All | 0 | Phase 2 | United States |
| 6 | NCT03807973 (ClinicalTrials.gov) | October 5, 2021 | 14/1/2019 | Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. | Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes. | Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy | Drug: [Zr-89]Oxine-labeled leukocytes PET/MRI | University of Alabama at Birmingham | NULL | Recruiting | 18 Years | 65 Years | All | 120 | Phase 1 | United States |
| 7 | NCT04885894 (ClinicalTrials.gov) | September 2021 | 11/5/2021 | An Examination of Cognitive Fatigue Using Functional Neuroimaging | An Examination of Cognitive Fatigue Using Functional Neuroimaging | Multiple Sclerosis, Relapsing-Remitting | Drug: Zeposia | Kessler Foundation | Celgene;Hackensack Meridian Health;St. Barnabas Medical Center | Not yet recruiting | 18 Years | 64 Years | All | 60 | United States | |
| 8 | NCT05730738 (ClinicalTrials.gov) | June 1, 2021 | 5/12/2021 | Dalfampridine in Egyptian Patients With Multiple Sclerosis | Effect of Dalfampridine on Gait Impairment, Cognition and Fatigue in Egyptian Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;Drug: Placebo | Ain Shams University | NULL | Recruiting | 18 Years | N/A | All | 100 | N/A | Egypt |
| 9 | NCT04448977 (ClinicalTrials.gov) | May 6, 2021 | 15/6/2020 | Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI | A Biomarker for Cognitive Fatigue Using Functional Imaging in MS | Multiple Sclerosis, Relapsing-Remitting | Drug: Ocrevus | Kessler Foundation | Hackensack Meridian Health | Recruiting | 18 Years | 64 Years | All | 60 | United States | |
| 10 | NCT04565431 (ClinicalTrials.gov) | March 19, 2021 | 25/8/2020 | Examining Effects of Tysabri on Cognitive Fatigue Using fMRI | Biomarker for Cognitive Fatigue Using Functional Imaging in Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Tysabri | Kessler Foundation | St. Barnabas Medical Center | Recruiting | 18 Years | 64 Years | All | 25 | United States | |
| 11 | NCT04267926 (ClinicalTrials.gov) | April 1, 2020 | 11/2/2020 | MitoQ for Fatigue in Multiple Sclerosis (MS) | MitoQ for Fatigue in Multiple Sclerosis: A Placebo Controlled Trial | Multiple Sclerosis;Fatigue | Drug: 20 mg MitoQ;Drug: Placebo;Drug: 40mg of MitoQ | VA Office of Research and Development | NULL | Recruiting | 18 Years | 70 Years | All | 60 | Phase 1/Phase 2 | United States |
| 12 | NCT04144257 (ClinicalTrials.gov) | March 12, 2020 | 28/10/2019 | Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue | Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue | Multiple Sclerosis | Drug: [F-18]PBR06;Drug: [C-11]Methylreboxetine | Brigham and Women's Hospital | U.S. Army Medical Research Acquisition Activity | Recruiting | 18 Years | 60 Years | All | 12 | Phase 1/Phase 2 | United States |
| 13 | NCT03910738 (ClinicalTrials.gov) | October 29, 2019 | 1/4/2019 | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting | Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection;Drug: Placebo 4 mL Solution for Injection;Procedure: MRI;Behavioral: Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities;Behavioral: Assessment of disability | University Hospital, Strasbourg, France | Bayer;Fédération Hospitalo-Universitaire NEUROGENYCS | Recruiting | 18 Years | 55 Years | Male | 40 | Phase 2 | France |
| 14 | NCT03759522 (ClinicalTrials.gov) | February 3, 2019 | 6/11/2018 | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. | Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy | Drug: DPA-714 PET/MRI | University of Alabama at Birmingham | NULL | Recruiting | 18 Years | 65 Years | All | 120 | Phase 1 | United States |
| 15 | NCT03621761 (ClinicalTrials.gov) | November 15, 2018 | 3/8/2018 | Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue | A Randomized Controlled Trial of Telephone-delivered Cognitive Behavioral-therapy, Modafinil, and Combination Therapy of Both Interventions for Fatigue in Multiple Sclerosis | Multiple Sclerosis | Behavioral: Telephone-based Cognitive Behavioral Therapy;Drug: Modafinil | University of Michigan | University of Washington;Patient-Centered Outcomes Research Institute;National Multiple Sclerosis Society | Completed | 18 Years | N/A | All | 343 | Phase 4 | United States |
| 16 | NCT03166800 (ClinicalTrials.gov) | September 15, 2018 | 23/5/2017 | MitoQ for Fatigue in Multiple Sclerosis | MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial | Multiple Sclerosis;Fatigue | Drug: Mitoquinone | Oregon Health and Science University | MitoQ Ltd | Completed | 18 Years | 70 Years | All | 9 | Phase 1/Phase 2 | United States |
| 17 | NCT03500289 (ClinicalTrials.gov) | August 10, 2018 | 4/4/2018 | Ketamine for Treatment of MS Fatigue | Ketamine for Treatment of Multiple Sclerosis-related Fatigue | Multiple Sclerosis;Fatigue | Drug: Ketamine;Drug: Midazolam | Johns Hopkins University | National Multiple Sclerosis Society | Completed | 18 Years | 65 Years | All | 18 | Phase 1/Phase 2 | United States |
| 18 | EUCTR2018-000721-31-SE (EUCTR) | 04/07/2018 | 24/04/2018 | A clincial study comparing the effectiveness of two doses of the drug Rituximab during long-term treatment of the neurological disease Multiple Sclerosis. | RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MSA randomized trial of long-term dosage of rituximab in multiple sclerosisThe RIDOSE-MS trial is a multi-centre trial of long-term treatment with rituximab in MS, randomised between two different dosing regimens. Population: Patients with RRMS that has completed the RIFUND-MS trial in either the rituximab or DMF arm. In addition, patients will be recruited that has not participated in the RIFUND trial but has been treated with rituximab with the same protocol as in the RIFUND trial as part of clinical practice.Intervention: Treatment with rituximab (Mabthera®) 500 mg every six months. Both the previous rituximab and DMF arms from the RIFUND trial will be treated with rituximab in the RIDOSE trial.Control: After one year of treatment in RIDOSE-MS, patients will be randomised 1:1 to either continue with 500 mg every 6 months or 500 mg every 12 months and continue on this treatment schedule for another 3 years.Outcome: Primary outcome will be the proportion of patients remaining with no evidence of disease activity (NEDA) -3 over the randomised period of 3 years. As secondary endpoints progression of disability, brain atrophy, cognitive function and level of serum Neurofilament-Light will be evaluated. In addition, Patient-related outcome scales measuring fatigue, work ability and treatment satisfaction will be analysed. - RIDOSE-MS | Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addition, patients will be recruited that has not participated in the RIFUND trial but has been treated with rituximab with the same protocol as in the RIFUND trial as part of clinical practice.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Mabthera Product Name: Mabthera INN or Proposed INN: RITUXIMAB Trade Name: Mabthera Product Name: Mabthera INN or Proposed INN: RITUXIMAB | Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 200 | Phase 2 | Sweden | ||
| 19 | NCT03000127 (ClinicalTrials.gov) | July 1, 2018 | 17/12/2016 | Testosterone for Fatigue in Men With MS | A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis | Multiple Sclerosis | Drug: AndroGel 1 % Topical Gel;Drug: Placebos | University of California, Los Angeles | Washington University School of Medicine | Withdrawn | 18 Years | 60 Years | Male | 0 | Phase 2 | United States |
| 20 | NCT03266965 (ClinicalTrials.gov) | March 23, 2018 | 4/7/2017 | Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach | Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach | Multiple Sclerosis | Drug: Carbidopa;Dietary Supplement: L-Histidine | University of Miami | United States Department of Defense | Completed | 18 Years | 60 Years | All | 18 | Phase 1 | United States |
| 21 | NCT03185065 (ClinicalTrials.gov) | October 4, 2017 | 9/6/2017 | Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis | Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis | Fatigue in Multiple Sclerosis | Drug: Amantadine;Drug: Modafinil;Drug: Methylphenidate;Drug: Placebos | Johns Hopkins University | Patient-Centered Outcomes Research Institute | Completed | 18 Years | N/A | All | 141 | Phase 3 | United States |
| 22 | EUCTR2017-001253-13-BE (EUCTR) | 23/08/2017 | 11/07/2017 | Does decresaed perfusion of the brain play a role in the reduced function of axons and the clinical disability and fatigue in patients with multiple sclerosis ? | Does cerebral hypoperfusion play a role in reduced axonal metabolism and clinical disability in patients with multiple sclerosis ? - ROCHIMS (Role of Cerebral Hypoperfusion In Multiple Sclerosis) | Patients suffering relapsing- remitting multiple sclerosis will be investigated in this study, with an EDSS score less or equal to 4.0. Patients must be older than 18 years old. There must not be any clinical evidence of an MS relpase within the 3 months prior to inclusion.;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Tracleer | UZ Brussel | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Belgium | ||
| 23 | NCT03110315 (ClinicalTrials.gov) | March 28, 2017 | 28/3/2017 | A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia | A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia | Multiple Sclerosis;Fatigue;Insomnia | Drug: Suvorexant;Drug: Placebo | Theodore R. Brown, MD MPH | Merck Sharp & Dohme Corp. | Completed | 18 Years | 75 Years | All | 34 | Phase 4 | United States |
| 24 | NCT03164018 (ClinicalTrials.gov) | March 7, 2017 | 29/3/2017 | Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis | Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis | Multiple Sclerosis | Drug: Fampridine | Genesis Pharma CNS & Specialty | NULL | Completed | 18 Years | N/A | All | 111 | Greece | |
| 25 | NCT03051646 (ClinicalTrials.gov) | January 13, 2017 | 8/2/2017 | Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis | A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis | Fatigue;Overheating | Drug: Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit;Drug: Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit | Columbia University | National Multiple Sclerosis Society | Completed | 18 Years | 60 Years | All | 12 | Early Phase 1 | United States |
| 26 | NCT02804594 (ClinicalTrials.gov) | October 1, 2016 | 3/6/2016 | A Study of Oxidative Pathways in MS Fatigue | A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis | Progressive Multiple Sclerosis;Fatigue | Drug: N-acetyl cysteine;Drug: Placebo | University of California, San Francisco | NULL | Completed | 18 Years | 75 Years | All | 15 | Phase 2 | United States |
| 27 | NCT02090348 (ClinicalTrials.gov) | June 2015 | 14/3/2014 | Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate | A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY) | Relapsing-Remitting Multiple Sclerosis;Multiple Sclerosis | Drug: dimethyl fumarate | Biogen | NULL | Withdrawn | 18 Years | N/A | Both | 0 | Phase 4 | NULL |
| 28 | NCT02315872 (ClinicalTrials.gov) | May 22, 2015 | 9/12/2014 | ACTH for Fatigue in Multiple Sclerosis Patients | The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis. | Multiple Sclerosis, Relapsing-Remitting | Drug: ACTH;Drug: Placebo | Providence Health & Services | Mallinckrodt | Completed | 18 Years | 65 Years | All | 8 | Phase 3 | United States |
| 29 | EUCTR2013-001025-53-ES (EUCTR) | 18/05/2015 | 03/03/2015 | A Study that evaluates Fatigue in Multiple Sclerosis Patients taking Tecfidera® (Dimethyl Fumarate) | A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsule (TECNERGY) - TECNERGY | Relapsing-Remitting Multiple Sclerosis MedDRA version: 17.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera (BG00012) Product Name: Tecfidera Product Code: BG00012 INN or Proposed INN: DIMETHYL FUMARATE Other descriptive name: DIMETHYL FUMARATE Trade Name: Tecfidera (BG00012) Product Name: Tecfidera Product Code: BG00012 INN or Proposed INN: DIMETHYL FUMARATE Other descriptive name: DIMETHYL FUMARATE | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 320 | Finland;Spain;Denmark;Norway;Netherlands;United Kingdom | |||
| 30 | NCT02391961 (ClinicalTrials.gov) | April 1, 2015 | 3/3/2015 | Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis | Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis | Multiple Sclerosis;Internuclear Ophthalmoplegia;Fatigue | Drug: Dalfampridine;Drug: Placebo | VA Office of Research and Development | NULL | Completed | 18 Years | 65 Years | All | 23 | Phase 2 | United States |
| 31 | EUCTR2013-001025-53-DK (EUCTR) | 05/03/2015 | 24/03/2014 | A Study that evaluates Fatigue in Multiple Sclerosis Patients taking Tecfidera® (Dimethyl Fumarate) | A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsule - TECNERGY | Relapsing-Remitting Multiple Sclerosis MedDRA version: 17.1;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 17.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Tecfidera (BG00012) Product Name: Tecfidera Product Code: BG00012 INN or Proposed INN: DIMETHYL FUMARATE Other descriptive name: DIMETHYL FUMARATE Trade Name: Tecfidera (BG00012) Product Name: Tecfidera Product Code: BG00012 INN or Proposed INN: DIMETHYL FUMARATE Other descriptive name: DIMETHYL FUMARATE | Biogen Idec Research Limited | NULL | Not Recruiting | Female: yes Male: yes | 320 | Phase 4 | Finland;Spain;Denmark;Norway;Netherlands;United Kingdom | ||
| 32 | NCT02286557 (ClinicalTrials.gov) | October 2014 | 16/10/2014 | Testing the Effects of Methylphenidate on Multiple Sclerosis | Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial | Fatigue in Multiple Sclerosis | Drug: Methelphenidate;Drug: Placebo | Kessler Foundation | NULL | Not yet recruiting | 18 Years | 65 Years | Both | 36 | Phase 2 | NULL |
| 33 | NCT01766063 (ClinicalTrials.gov) | December 6, 2012 | 7/12/2012 | Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon | BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon® Treated MS Patients | Multiple Sclerosis | Drug: Interferon beta-1b (Betaferon, BAY 86-5046) | Bayer | NULL | Completed | 18 Years | N/A | All | 138 | Germany | |
| 34 | NCT01879202 (ClinicalTrials.gov) | December 2012 | 7/11/2012 | Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis | Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study. | Multiple Sclerosis;Fatigue | Drug: Methylphenidate modified release;Drug: Maltodextrin | Medical University of Vienna | NULL | Recruiting | 18 Years | N/A | Both | 96 | Phase 2 | Austria |
| 35 | NCT01720849 (ClinicalTrials.gov) | December 2012 | 31/10/2012 | Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis | Multiple Sclerosis;EDSS 4-7 | Drug: Fampyra | Vestre Viken Hospital Trust | NULL | Recruiting | 18 Years | N/A | Both | 50 | N/A | Norway | |
| 36 | EUCTR2012-003418-15-AT (EUCTR) | 23/10/2012 | 09/11/2012 | Methylphenidate modified release as treatment of MS-associated fatigue. | Methylphenidate modified release as treatment option of MS-associated fatigue. A single-center randomized double-blind placebo-controlled trial. | Fatigue is a very common symptom in multiple sclerosis. Its management comprises nonpharmacologic approaches like exercise, cooling procedures and energy conservation programs and as second step pharmacologic therapy. Until now, Amantadine, Modafinil or antidepressants have been used off-label among others, with some success. Until now, methylphenidate has been successfully used to treat fatigue in HIVand parkinson´s disease, data on its efficacy in MS are not available.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Ritalin LA 20mg capsules Product Name: Methylphenidate modified release 20 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE Trade Name: Ritalin LA 30mg capsules Product Name: Methylphenidate modified release 30 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE Trade Name: Ritalin LA 40mg capsules Product Name: Methylphenidate modified release 40 mg INN or Proposed INN: METHYLPHENIDATE HYDROCHLORIDE | Medizinische Universität Wien | NULL | Not Recruiting | Female: yes Male: yes | 96 | Phase 2 | Austria | ||
| 37 | NCT01667497 (ClinicalTrials.gov) | September 2012 | 13/8/2012 | Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? | Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? A Cross Over Study | Cognitive Fatigue | Drug: Fampridine SR;Drug: Placebo | London Health Sciences Centre | NULL | Completed | 18 Years | 64 Years | Both | 60 | Phase 2/Phase 3 | Canada |
| 38 | NCT01718678 (ClinicalTrials.gov) | May 2012 | 28/10/2012 | Effect of Melatonin on Multiple Sclerosis Related Fatigue | Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis | Fatigue | Drug: Melatonin;Drug: Placebo | Isfahan University of Medical Sciences | NULL | Completed | 18 Years | 55 Years | Both | 44 | Phase 2 | Iran, Islamic Republic of |
| 39 | NCT01591551 (ClinicalTrials.gov) | March 2012 | 22/4/2012 | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness | NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Relapsing Forms of Multiple Sclerosis Experiencing Fatigue or Sleepiness | Multiple Sclerosis, Relapsing-Remitting | Drug: Natalizumab (Tysabri) | Cornerstone Health Care, PA | Biogen Idec | Completed | 18 Years | 65 Years | Both | 37 | Phase 4 | United States |
| 40 | NCT01516554 (ClinicalTrials.gov) | February 2012 | 19/1/2012 | Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients | A Randomized, Controlled Crossover Trial Evaluating Oral Testosterone in the Treatment of Fatigue in Male Multiple Sclerosis Patients | Multiple Sclerosis;Fatigue | Drug: Testosterone undecanoate;Drug: placebo | Health Sciences Centre, Winnipeg, Manitoba | University of Manitoba;Consortium of Multiple Sclerosis Centers;Manitoba Medical Service Foundation | Terminated | 18 Years | 65 Years | Male | 3 | Phase 2 | Canada |
| 41 | EUCTR2011-002969-38-DE (EUCTR) | 08/11/2011 | 30/09/2011 | A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase | A 6-month, multicenter, randomized, controlled parallel group study to evaluate the effect of physical training on fatigue in patients with relapsing-remitting multiple sclerosis treated with fingolimod (Gilenya®), followed by a 6 month optional extension phase - | Fatigue in Patients with relapsing remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720 Other descriptive name: Fingolimod Hydrochloride | Novartis Pharma GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Germany | ||||
| 42 | NCT01444300 (ClinicalTrials.gov) | September 2011 | 20/9/2011 | Dalfampridine for Imbalance in Multiple Sclerosis | Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study | Multiple Sclerosis;Fatigue | Drug: Dalfampridine;Drug: Placebo | Oregon Health and Science University | Acorda Therapeutics | Completed | 20 Years | 59 Years | All | 24 | Phase 2 | United States |
| 43 | EUCTR2010-023678-38-IT (EUCTR) | 20/04/2011 | 02/02/2011 | High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND | High-field structural and functional MRI to investigate the substrates of fatigue in multiple sclerosis and to monitor the effect of tailored treatments.Pharmacological substudy. - ND | patients with multiple sclerosis MedDRA version: 9.1;Level: PT;Classification code 10028245 | Trade Name: MANTADAN*20CPR 100MG INN or Proposed INN: Amantadine Trade Name: AMPYRA INN or Proposed INN: Ampyra | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | NULL | Not Recruiting | Female: yes Male: yes | Italy | ||||
| 44 | EUCTR2011-000150-31-IT (EUCTR) | 13/04/2011 | 28/12/2011 | EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. | EFFECTS OF GLATIRAMER ACETATE ON TISSUE DAMAGE, CORTICAL FUNCTIONS AND FATIGUE IN MULTIPLE SCLEROSIS: A MORPHO-FUNCTIONAL MRI STUDY. | Multiple Sclerosis patients MedDRA version: 14.1;Level: HLGT;Classification code 10012303;Term: Demyelinating disorders;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;Level: SOC;Classification code 10029205;Term: Nervous system disorders;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: COPAXONE INN or Proposed INN: Glatiramer acetate | FONDAZIONE DON CARLO GNOCCHI ONLUS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 45 | NCT01712373 (ClinicalTrials.gov) | December 2010 | 19/10/2012 | Ginseng in Treatment of Fatigue in Multiple Sclerosis | Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis | Fatigue | Drug: Ginseng;Drug: Placebo | Isfahan University of Medical Sciences | NULL | Completed | 18 Years | 50 Years | Both | 60 | Phase 2 | Iran, Islamic Republic of |
| 46 | NCT01149525 (ClinicalTrials.gov) | June 2010 | 21/6/2010 | Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis | A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis | Multiple Sclerosis | Drug: L-Carnitine;Drug: Placebo | University Hospital, Bordeaux | NULL | Completed | 18 Years | N/A | All | 59 | Phase 3 | France |
| 47 | NCT01354665 (ClinicalTrials.gov) | May 2010 | 16/5/2011 | Depression and Fatigue in MS Patients Treated With Betaferon. | The Short-term Effect of Immunomodulatory Treatment With Interferon Beta-1b (Betaferon) on Fatigue and Depression in First-time Treated Patients With Relapsing-remitting Multiple Sclerosis. | Multiple Sclerosis | Biological: Interferon beta-1b (Betaferon, BAY86-5046) | Bayer | NULL | Completed | 18 Years | N/A | Both | 567 | N/A | Poland |
| 48 | EUCTR2009-015934-30-FR (EUCTR) | 02/02/2010 | 19/01/2010 | étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP | étude randomisée en double insu et crossover comparant l’efficacité de la L-carnitine à un placebo dans le traitement de la fatigue dans la sclérose en plaques - FACTSEP | sclérose en plaquefatigue MedDRA version: 12.0;Level: LLT;Classification code 10028245;Term: Multiple sclerosis | Trade Name: levocarnil Product Name: Levocarnil Product Code: na INN or Proposed INN: L-carnitine | CHU de Bordeaux | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | France | |||
| 49 | NCT00981084 (ClinicalTrials.gov) | September 2009 | 18/9/2009 | Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS) | The Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis: a Double-Blind Randomized Crossover Study | Multiple Sclerosis | Drug: armodafinil | University of Missouri, Kansas City | University of Kansas | Completed | 18 Years | 60 Years | All | 33 | Phase 2/Phase 3 | United States |
| 50 | NCT01075880 (ClinicalTrials.gov) | May 2009 | 24/2/2010 | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® | Post-Authorization Observational Study to Evaluate Cognition and Fatigue in RRMS Patients Treated With Rebif | Multiple Sclerosis, Relapsing-Remitting | Drug: Rebif (Interferon beta-1a) | Merck KGaA | Merck spol.s.r.o., Czech Republic | Completed | 18 Years | 65 Years | Both | 300 | N/A | Czech Republic |
| 51 | EUCTR2008-008065-35-SE (EUCTR) | 13/03/2009 | 17/12/2008 | A multi-centre and prospective trial to evaluate the effects on mul-tiple sclerosis related fatigue during treatment with Tysabri® in patients with relapsing remitting multiple sclerosis over the course of 12 months - TYNERGY | Mutiple sclerosis related fatigue in subjects with relapsing remitting multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1;Classification code 10016256;Term: Fatigue | Trade Name: Tysabri | BiogenIdec A/S | NULL | Not Recruiting | Female: yes Male: yes | 200 | Sweden | ||||
| 52 | NCT00467584 (ClinicalTrials.gov) | July 2007 | 26/4/2007 | Aspirin for Treatment of Multiple Sclerosis-Related Fatigue | Aspirin for Treatment of Multiple Sclerosis-Related Fatigue | Multiple Sclerosis;Fatigue | Drug: High Dose Aspirin (1300 mg/day);Drug: Low Dose Aspirin (162 mg/day);Drug: Placebo | Mayo Clinic | National Multiple Sclerosis Society | Terminated | 18 Years | 65 Years | All | 62 | Phase 3 | United States |
| 53 | NCT00594087 (ClinicalTrials.gov) | December 2006 | 3/1/2008 | Eszopiclone for Improving Sleep in Multiple Sclerosis (MS) | Eszopiclone for Improving Sleep Continuity in MS Patients With Sleep Disturbances and Its Impact on Daytime Fatigue | Relapsing Remitting Multiple Sclerosis;Sleep Initiation and Maintenance Disorders;Fatigue | Drug: eszopiclone;Other: placebo | University of Vermont | NULL | Completed | 18 Years | 64 Years | Both | 30 | N/A | United States |
| 54 | NCT00882453 (ClinicalTrials.gov) | August 2006 | 15/4/2009 | Physical Activity and Fatigue in Early Multiple Sclerosis (MS) | Betaferon Treatment and Exercise Data Gathering IN Early MS | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 18 Years | N/A | Both | 1739 | N/A | Australia;Austria;Bahrain;Belgium;Canada;Colombia;Czech Republic;Denmark;Egypt;France;Germany;Greece;Indonesia;Israel;Italy;Jordan;Kazakhstan;Korea, Republic of;Kuwait;Lebanon;Mexico;Netherlands;Norway;Oman;Portugal;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;United Arab Emirates;United Kingdom |
| 55 | NCT00342381 (ClinicalTrials.gov) | June 2006 | 20/6/2006 | Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation | Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation | Multiple Sclerosis;Fatigue | Drug: 3,4-diaminopyridine;Drug: Placebo | University of Aarhus | The Danish Multiple Sclerosis Society | Completed | 18 Years | 55 Years | Both | 120 | Phase 2 | Denmark |
| 56 | EUCTR2005-005211-21-FI (EUCTR) | 17/01/2006 | 07/12/2005 | A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years | A long term follow up of relapsing remitting multiple sclerosis patients who have been treated with intereron beta -1b (Betaferon) at least 5 years | Remitting relapsing multiple sclerosis (RRMS) is one of the most common diseases of the central nervous system. The cause of MS is not yet known but it is a result of damage to myelin. Symptoms vary widely and include blurred vision, weak limbs, tingling sensations, unsteadiness and fatigue. | Trade Name: Betaferon Product Name: Betaferon INN or Proposed INN: Beta-1b interferoni | Schering Oy | NULL | Not Recruiting | Female: yes Male: yes | 80 | Finland | |||
| 57 | NCT00754832 (ClinicalTrials.gov) | September 2005 | 16/9/2008 | American Ginseng Treatment for Multiple Sclerosis Related Fatigue | A Double-blinded, Placebo-controlled Crossover Pilot Study of American Ginseng Treatment for Multiple Sclerosis Related Fatigue | Multiple Sclerosis | Drug: American ginseng extract HT-1001;Drug: placebo | Oregon Health and Science University | National Multiple Sclerosis Society | Completed | 18 Years | 70 Years | All | 56 | Phase 2 | United States |
| 58 | NCT00220506 (ClinicalTrials.gov) | September 2005 | 14/9/2005 | Fatigue Treatment Using Provigil | Fatigue Treatment Using Provigil in Patients With Relapsing Remitting Multiple Sclerosis | All Multiple Sclerosis Patients | Drug: Provigil | Sheba Medical Center | NULL | Recruiting | 18 Years | 55 Years | Both | 50 | N/A | Israel |
| 59 | NCT00190268 (ClinicalTrials.gov) | February 2005 | 13/9/2005 | Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis | Multicentric Study, Comparative, Randomized, in Double Knowledge of the Effectiveness (Versus Placebo) of a Salt Of 3,4 - Diaminopyridine in the Treatment of Tiredness During the Multiple Sclerosis | Multiple Sclerosis | Drug: 3,4-diaminopyridine | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 18 Years | 60 Years | Both | 126 | Phase 3 | France |
| 60 | NCT00267319 (ClinicalTrials.gov) | June 2003 | 19/12/2005 | FOCUS Fatigue Outcome in Copaxone USers | Fatigue Outcomes of Copaxone Users in Relapsing-remitting Multiple Sclerosis | Multiple Sclerosis | Drug: Glatiramer acetate | Sanofi | NULL | Completed | 18 Years | N/A | Both | 111 | Phase 4 | Czech Republic |